^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TT11

i
Other names: TT11, CD30.CAR-T cell therapy, TT11 CD30 CAR Ts, CD30.CAR-T, ATLCAR.CD30 cell therapy, ATLCAR.CD30 cells, CAR.CD30 T cell therapy, TT-11, TT 11
Company:
Baylor Scott & White Research Institute, Tessa Therap, UNC Lineberger Comprehensive Cancer Center
Drug class:
CD30-targeted CAR-T immunotherapy
24d
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2040 --> Aug 2038 | Trial primary completion date: Aug 2025 --> Sep 2027
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
TT11
5ms
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (clinicaltrials.gov)
P1/2, N=31, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
Enrollment open • IO biomarker
|
TT11 • ATLCAR.CD30.CCR4 cells
11ms
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Recruiting, UNC Lineberger Comprehensive Cancer Center
Trial completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
cyclophosphamide • fludarabine IV • TT11
11ms
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (clinicaltrials.gov)
P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression • ALK negative • TNFRSF8 negative
|
TT11
over1year
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2038 --> Aug 2040 | Trial primary completion date: Aug 2023 --> Aug 2025
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
TT11
over1year
Combined autologous CD30.CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study) (ICML 2023)
Two patients had cytokine release syndrome (Grade 1), which resolved without use of steroid or tocilizumab. Preliminary data demonstrated favorable safety profile and promising anti-tumor responses of CD30.CAR-T combined with nivo in r/r cHL patients after failure of frontline therapy. Evaluation of 15 patients enrolled is ongoing, and the clinical and ctDNA-MRD data will be presented at the meeting.
Clinical • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression • PD-L2 overexpression
|
Opdivo (nivolumab) • Actemra IV (tocilizumab) • TT11
over1year
CERTAIN: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=21, Active, not recruiting, Tessa Therapeutics | Trial primary completion date: Mar 2023 --> Nov 2022
Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
TT11
over1year
ACTION: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (clinicaltrials.gov)
P1b, N=15, Active, not recruiting, Tessa Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Checkpoint inhibition
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
Opdivo (nivolumab) • fludarabine IV • TT11
over1year
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (clinicaltrials.gov)
P1, N=60, Recruiting, Baylor College of Medicine | Trial completion date: Feb 2036 --> Feb 2040
Trial completion date • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
TT11
over1year
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial primary completion date: Aug 2023 --> Feb 2028
Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
cyclophosphamide • fludarabine IV • TT11
almost2years
CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
P2, N=18, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
Enrollment open
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
cyclophosphamide • fludarabine IV • TT11
almost2years
Longitudinal Dynamics of Clonal Hematopoiesis in Patients Receiving Anti-CD30 CAR T-Cell Therapy (TCT-ASTCT-CIBMTR 2023)
The recurrence of DNMT3A and PPM1D mutations indicates the selective influence of prior chemotherapeutics. Given the increasing number of patients receiving CAR-T therapy, further work must determine if high CH prevalence in this cohort is predictive of increased long-term complications in survivors.
Clinical • CAR T-Cell Therapy • IO biomarker
|
DNMT3A (DNA methyltransferase 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)
|
DNMT3A mutation • TNFRSF8 expression • PPM1D mutation
|
TT11
almost2years
CD30 CAR for CD30+ NSGCT (clinicaltrials.gov)
P2, N=18, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
New P2 trial
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
cyclophosphamide • fludarabine IV • TT11
almost2years
Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION) (ASH 2022)
The efficacy and safety profile of programmed death (PD)-1 checkpoint inhibitors, nivolumab and pembrolizumab, in cHL have been well demonstrated (Chen et al., 2017; Kuruvilla et al., 2021; Younes et al., 2016), with FDA approval for r/r cHL. PD-1 checkpoint inhibitors, in combination with CD30-directed antibody therapy (brentuximab vedotin) or other chemotherapies, have also shown high efficacy in this setting (Advani et al., 2021; Mei et al., 2022; Moskowitz et al., 2021)...Following a leukapheresis procedure for manufacture of CD30.CAR-T cells, patients will be treated with 4 cycles of nivolumab every 4 weeks (Q4W), and a single infusion of CD30.CAR-T cells (given between nivolumab Cycles 2 and 3, and after lymphodepletion with bendamustine and fludarabine)...The key secondary objective is to evaluate potential anti-tumor activity, as assessed by the CR rate of autologous CD30.CAR-T in combination with nivolumab at EOT in 14 evaluable patients, as per Lugano Classification Revised Response System for malignant lymphoma (Cheson et al., 2014). Other secondary objectives are to assess the overall response rate (ORR), duration of response (DOR), and progression-free survival (PFS) of patients in the ASCT and non-ASCT groups.This study is ongoing and one patient has been enrolled to date.
Clinical • P1/2 data • Combination therapy • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Adcetris (brentuximab vedotin) • bendamustine • fludarabine IV • TT11
almost2years
Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma (ASH 2022)
The anti-PD-1 antibodies nivolumab and pembrolizumab have both been studied in phase II studies in patients with r/r cHL with ORR ranging between 65-87% and median progression free survival (PFS) ranging from 13-15 months...This study is the first to describe CD30.CAR-T expansion following anti-PD-1 therapy. While further analysis is warranted to assess for CD30.CAR-T functionality after anti-PD-1 exposure, our data suggest that anti-PD-1 therapy may rescue CD30.CAR T cells, supporting further investigations in patients with cHL.
Clinical • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • CCR4 (C-C Motif Chemokine Receptor 4)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • TT11
2years
Ultrasensitive Circulating Tumor DNA (ctDNA) Dynamics after Autologous CD30.CAR-T Cell Therapy for Relapsed or Refractory (r/r) Classical Hodgkin Lymphoma (CHARIOT Trial) (ASH 2022)
A single infusion of CD30.CAR-T therapy rapidly induces MRD negativity in a significant subset of patients at Day 42. ctDNA as exploratory biomarker will be further evaluated in Pivotal part of the study.
CAR T-Cell Therapy • IO biomarker • Circulating tumor DNA
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TT11
2years
Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial) (ASH 2022)
Methods This is a Phase 2 single arm, multi-center study, enrolling patients (12-75 years) with cHL progression after at least 3 lines of therapy, including chemotherapy, brentuximab vedotin, and anti-programmed cell death (PD)-1 antibodies...The patients were treated with CD30.CAR-T cells, after lymphodepletion chemotherapy using bendamustine and fludarabine, with an allowable dose range of 2.0 to 2.7 × 108 CD30.CAR-T cells per m2...The CD30.CAR-T cells showed good expansion and persistence after infusion. The efficacy, safety and exploratory biomarkers of CD30.CAR-T will be further evaluated in the Pivotal segment of this Phase 2 study.
Clinical • CAR T-Cell Therapy • IO biomarker
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • IL15 (Interleukin 15)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin) • bendamustine • fludarabine IV • TT11
over2years
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (clinicaltrials.gov)
P1, N=66, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2022 --> Apr 2026
Trial primary completion date • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
cyclophosphamide • fludarabine IV • TT11
over2years
CERTAIN: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=21, Active, not recruiting, Tessa Therapeutics | Recruiting --> Active, not recruiting
Enrollment closed
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
TT11
over2years
Enrollment open • Combination therapy • Checkpoint inhibition
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
Opdivo (nivolumab) • fludarabine IV • TT11
over2years
New P1 trial • Combination therapy • Checkpoint inhibition
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
Opdivo (nivolumab) • fludarabine IV • TT11
over2years
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) (clinicaltrials.gov)
P2, N=97, Active, not recruiting, Tessa Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Feb 2036 --> Mar 2037 | Trial primary completion date: Feb 2023 --> May 2025
Enrollment closed • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
fludarabine IV • TT11
over2years
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas (clinicaltrials.gov)
P1, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression • ALK negative • TNFRSF8 negative
|
TT11
almost3years
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Aug 2037 --> Aug 2038 | Trial primary completion date: Aug 2022 --> Aug 2023
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
cyclophosphamide • fludarabine IV • TT11
almost3years
Evaluating the Safety and Clinical Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma (TCT-ASTCT-CIBMTR 2022)
To assess the safety and clinical activity of banked CD30.CAR EBVSTs, we enrolled patients with multiply relapsed (median of 4 prior lines of therapy; range 3-5) or refractory CD30-positive lymphomas in a Phase 1 dose escalation study using 4 × 10 7 , 1 × 10 8 or 4 × 10 8 CD30.CAR EBVSTs infused after cytoreduction with cyclophosphamide and fludarabine...In summary, banked CD30.CAR EBVSTs can safely be given to allogeneic recipients and may cause significant tumor responses including complete remissions. These cells may be a suitable platform for other “off-the-shelf” CAR-T cell therapies.
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
|
cyclophosphamide • fludarabine IV • TT11
3years
Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial) (ASH 2021)
CD30 is a validated target for classical Hodgkin Lymphoma (cHL), as demonstrated by the activity of the anti-CD30 antibody drug conjugate, brentuximab vedotin (BV), making it an attractive target for CAR-T therapy in this disease...Eligible patients undergo leukapheresis for manufacture of CD30.CAR-T cells, followed by LD chemotherapy using bendamustine and fludarabine, prior to infusion of CD30.CAR-T with an allowable dose range of 2.0 to 2.7 × 10 8 CD30.CAR-T cells per m 2...Conclusion Preliminary data from the Pilot segment of this study confirms favorable safety profile and excellent anti-tumor responses of CD30.CAR-T in heavily-treated R/R cHL patients. The efficacy and safety of CD30.CAR-T will be further evaluated in the Pivotal segment of this Phase 2 study.
Clinical • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
Adcetris (brentuximab vedotin) • bendamustine • fludarabine IV • TT11
3years
CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients (ASH 2021)
Five patients, 3 HL and 2 NHL, were enrolled on a phase Ib/II study and received 1x10 8 CD30.CAR-T cells/m 2 , as treatment for relapsed disease, after lymphodepletion with bendamustine and fludarabine (NCT02690545). HL patients had failed multiple lines of therapies (5-6), including 2 with prior pembrolizumab, 2 with prior ASCT, and all 3 with prior brentuximab vedotin (BV) and radiation therapy...The ALK negative patient had been treated with 3 prior lines of therapy and the ALK positive patient had been treated with 6 lines of prior therapy including ASCT and two ALK inhibitors, crizotinib and brigatinib...He responded to antibacterial agents and two doses of tocilizumab, as well as brief supplemental oxygen by nasal cannula... Our studies show that CD30.CAR-T cells are well tolerated in pediatric patients. CRs were observed in all heavily pre-treated and refractory HL patients, highlighting the potential of this strategy. All patients treated on both studies had previously received BV, which suggests CD30.CAR-T cells are effective even post BV progression.
Clinical
|
CD19 (CD19 Molecule) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 expression • ALK negative
|
Keytruda (pembrolizumab) • Xalkori (crizotinib) • Alunbrig (brigatinib) • Adcetris (brentuximab vedotin) • bendamustine • fludarabine IV • Actemra IV (tocilizumab) • TT11
3years
Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma (ASH 2021)
To assess the safety and activity of banked CD30.CAR EBVSTs, we treated patients with multiply relapsed (median of 4 prior lines of therapy; range 3-5) or refractory CD30-positive lymphomas in a Phase 1 dose escalation study using 4 × 10 7 , 1 × 10 8 or 4 × 10 8 CD30.CAR EBVSTs infused after lymphodepletion with cyclophosphamide and fludarabine...Thus banked CD30.CAR EBVSTs can safely be given to allogeneic recipients and may cause significant tumor responses including complete remissions. These cells may be a suitable platform for other “off-the-shelf” CAR-T cell therapies.
Clinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
|
cyclophosphamide • fludarabine IV • TT11
over3years
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (clinicaltrials.gov)
P1, N=66, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2021 --> Apr 2022
Trial primary completion date • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
fludarabine IV • TT11 • cyclophosphamide intravenous
over3years
Clinical • Trial completion date • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
fludarabine IV • TT11
over3years
CERTAIN: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=21, Recruiting, Tessa Therapeutics | Trial completion date: Feb 2023 --> Mar 2036 | Initiation date: Nov 2020 --> Mar 2021 | Trial primary completion date: Feb 2022 --> Mar 2023
Clinical • Trial completion date • Trial initiation date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
TT11
almost4years
Clinical • Enrollment open • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
fludarabine IV • TT11
almost4years
Clinical • Enrollment open
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
TT11
almost4years
Clinical • Trial initiation date • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
fludarabine IV • TT11
4years
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
P1/2, N=40, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Feb 2037 --> Aug 2038 | Trial primary completion date: Feb 2022 --> Aug 2023
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
TT11 • ATLCAR.CD30 cell therapy
4years
Clinical • New P1 trial
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
TT11